Takeover Bids


  • Hillshire gets takeover offer from Pilgrim's Pride  Tuesday, 27 May 2014 | 9:05 AM ET

    The "Squawk on the Street" news team discusses the report that Pilgrim's Pride is offering to acquire Hillshire Brands for $6.4 billion.

  • Cramer eyes food fight  Tuesday, 27 May 2014 | 8:53 AM ET

    Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell. Today Cramer shares his thoughts on Pilgrim Pride's bid for Hillshire Brands.

  • Plotting Pfizer's next move  Tuesday, 27 May 2014 | 6:20 AM ET

    John Eade, Argus Research, discusses Pfizer's likely next move after abandoning its attempt to buy AstraZeneca. There's a good chance AstraZeneca management could ask Pfizer to come back to the table, says Eade.

  • Pfizer's final bid rejected  Monday, 19 May 2014 | 2:17 PM ET

    $117 billion was not enough for AstraZeneca. CNBC's Meg Tirrell looks at Pfizer and AstraZeneca's stocks.

  • Next big takeover  Monday, 19 May 2014 | 2:12 PM ET

    CNBC's Herb Greenberg plays a game of "deal or no deal" and rounds up potential next takeover targets.

  • Faber Report: Hillshire to acquire Pinnacle  Monday, 12 May 2014 | 10:16 AM ET

    CNBC's David Faber reports Hillshire Brands is buying Pinnacle Foods. And Faber comments on Allergan's rejection of Valeant's takeover bid.

  • What Cramer expects from IPO market  Monday, 12 May 2014 | 9:08 AM ET

    Allergan has rejected a $47 billion takeover bid by Valeant Pharmaceuticals. The "Squawk on the Street" news team discuss m&a in pharmaceuticals and the IPO market.

  • Bill Ackman, Pershing Square Capital Management, explains what led him to reach out to activist investor Carl Icahn. Ackman calls him "a charming guy."

  • Bill Ackman, Pershing Square Capital Management, weighs in on the Valeant and Allergan controversy and long-term shareholder activism.

  • Ackman: No alternative to Fannie and Freddie  Monday, 5 May 2014 | 4:01 PM ET

    CNBC's Scott Wapner speaks to Bill Ackman, Pershing Square Capital Management, about the "winding down" of the old version of Fannie and Freddie and discusses the importance of reform to their programs.

  • AstraZeneca rejects new Pfizer bid  Friday, 2 May 2014 | 9:07 AM ET

    AstraZeneca has rejected Pfizer's sweetened bid claiming it undervalues the company. The "Squawk on the Street" news team shares their thoughts on the latest bid and the U.S. tax code.

  • Pfizer prepares sweeter bid for AstraZeneca Thursday, 1 May 2014 | 2:49 PM ET

    Pfizer CEO Ian Read recently met with U.K.-based investors to discuss a second bid for AstraZeneca, valuing the firm at $106 billion, sources said.

  • GE's Immelt: Alstom deal will be executed  Wednesday, 30 Apr 2014 | 1:19 PM ET

    Alstom has until June 2 to review General Electric's $13.5 billion bid for its energy assets, reports CNBC's Mary Thompson.

  • GE's big bid for Alstom  Wednesday, 30 Apr 2014 | 10:47 AM ET

    Alstom is accepting GE's $13.5 billion bid for its energy assets, reports CNBC's Mary Thompson.

  • GE CEO confident Alstrom deal will go through  Wednesday, 30 Apr 2014 | 9:36 AM ET

    Jeffrey Immelt, General Electric chairman & CEO, discusses how the synergies between GE and Alstrom will likely drive earnings and increase the company's industrial mix.

  • Alstom backs GE bid but Siemens sweetens deal  Wednesday, 30 Apr 2014 | 7:02 AM ET

    CNBC's Mary Thompson reports the latest details on General Electric's attempt to acquire French company Alstom.

  • Alstrom bidding war standoff: GE vs. SI  Wednesday, 30 Apr 2014 | 6:07 AM ET

    Nicholas Heymann, William Blair analyst, discusses General Electric's attempt to acquire Alstrom but Germany's Siemens AG is not giving up its pursuit either. Currently GE has the green light from Alstrom shareholders, says Heymann.

  • Siemens will make Alstom offer: Report  Tuesday, 29 Apr 2014 | 11:11 AM ET

    CNBC's David Faber reports Siemens will make an offer for Alstonm.

  • Pfizer engaging in legal tax avoidance: Bernstein  Monday, 28 Apr 2014 | 3:21 PM ET

    Jared Bernstein, senior fellow at The Center on Budget and Policy Priorities, and Rep. Todd Young, R-Ind., discusses how America's broken corporate tax code can cause companies, like Pfizer, to incorporate outside the U.S.

  • Pfizer, AstraZeneca about drug pipeline: Pro  Monday, 28 Apr 2014 | 11:23 AM ET

    Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.